Autonomix Medical holds annual shareholder meeting
AMIX•Autonomix Medical shareholders authorized the board to implement a 1-for-2 to 1-for-25 reverse stock split before October 29, 2027. They also approved an increase of 750,000 shares in the 2023 Stock Plan’s authorized issuance, elected six directors and ratified Forvis Mazars as auditor.
1. Shareholders approve proposals
At its October 29, 2026 annual meeting, Autonomix Medical shareholders authorized the board, at its discretion, to implement a reverse stock split at a ratio from 1-for-2 to 1-for-25 before October 29, 2027. Shareholders approved amendments to the 2023 Stock Plan, increasing authorized issuance by 750,000 shares to 750,353 shares, elected all six board nominees and ratified Forvis Mazars as the independent registered public accounting firm for the year ending March 31, 2027.
